Cadrenal Therapeutics Presents VLX-1005 Data at Lytham Partners 2026 Investor Healthcare Summit
I'm PortAI, I can summarize articles.
Cadrenal Therapeutics Inc. presented data on VLX-1005, a selective 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), during a webcast at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. The company discussed its progress and ongoing FDA engagement regarding a potential pivotal Phase 3 registration study. The webcast is available for replay on the conference website.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments